This PDF is the current document as it appeared on Public Inspection on 04/25/2014 at 08:45 am.
By Notice dated January 15, 2014, and published in the Federal Register on February 4, 2014, 79 FR 6630, S & B Pharma, Inc., DBA Norac Pharma, 405 S. Motor Avenue, Azusa, California 91702-3232, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:
The company plans to import the listed controlled substances for internal use, and to manufacture bulk intermediates for sale to its customers.
On February 10, 2014, S & B Pharma, Inc., withdrew its request for the addition of Fentanyl (9801) to this registration.
No comments or objections have been received. The DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of S & B Pharma, Inc. to import the basic classes of controlled substances is consistent with the public interest and in accordance with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA has investigated S & B Pharma, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.Start Printed Page 23375
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.Start Signature
Dated: April 21, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2014-09578 Filed 4-25-14; 8:45 am]
BILLING CODE 4410-09-P